587 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
SNY Sanofi $44.6 $112.25B Uptrend
Local fallout from Sanofi’s $11.6B Bioverativ deal: 3 things to know http://feeds.bizjournals.com/~r/industry_6/~3/lwkZzhcXGHk/local-fallout-from-sanofi-s-11-6b-bioverativ-deal.html Jan 22, 2018 - Waltham-based Bioverativ, a hemophilia drugmaker that was spun out of Biogen last year, has around 275 employees in the state.
Biotech Forum Daily Digest For January 21st https://seekingalpha.com/article/4139080-biotech-forum-daily-digest-january-21st?source=feed_sector_healthcare Jan 22, 2018 - Biotech continues to underperform the overall market as money flow heads to the more direct beneficiaries of tax reform within sectors and industries. However, that could very well change if M&A activ
Sanofi to Acquire Haemophilia Focused Bioverativ, Stock Dips http://www.zacks.com/stock/news/289575/sanofi-to-acquire-haemophilia-focused-bioverativ-stock-dips?cid=CS-ZC-FT-289575 Jan 22, 2018 - Sanofi (SNY) is set to acquire blood disorder focused biopharmaceutical company, Bioverativ, for $11.6 billion.
Will These 4 Large-Cap Drug Stocks Be Big Winners This Earnings Season? http://www.zacks.com/stock/news/289558/will-these-4-large-cap-drug-stocks-be-big-winners-this-earnings-season?cid=CS-ZC-FT-289558 Jan 22, 2018 - Here is a look at four large-cap pharma and biotech stocks including Merck (MRK) that could surpass earnings expectations in the fourth quarter.
Sanofi, Facing Threat From Generics, Moves to Buy Hemophilia Drug Maker https://www.nytimes.com/2018/01/22/business/dealbook/sanofi-hemophilia-bioverativ.html?partner=rss&emc=rss Jan 22, 2018 - The $11.6 billion deal for Bioverativ would bolster the French pharmaceutical giant’s portfolio as it faces falling sales for its diabetes drug, Lantus.
Sanofi to buy Bioverativ, Biogen's hemophilia spinout, for $11.6B http://feeds.bizjournals.com/~r/industry_6/~3/kQJDLcCpRMU/sanofi-to-buy-bioverativ-biogens-hemophilia.html Jan 22, 2018 - Paris-based Sanofi SA, the state’s largest biotech employer, said Monday that it will buy hemophilia drugmaker Bioverativ for $11.6 billion, one year after the Waltham company was spun out of Biogen. Sanofi (NYSE: SNY), the parent company of Cambridge-based Sanofi Genzyme, said it will pay $105 per share in cash for Bioverativ (Nasdaq: BIVV), which spun out of Biogen (Nasdaq: BIIB) last January. The price represents a 63 percent premium to Bioverativ’s share price as of Friday. The deal is…
Wall Street Breakfast: Futures Slip As Shutdown Continues https://seekingalpha.com/article/4139030-wall-street-breakfast-futures-slip-shutdown-continues?source=feed Jan 22, 2018 - As the government shutdown enters a third day, U.S. futures are edging down, the dollar is pulling back slightly and Treasury yields are touching 3 1/2-year highs. We have to see if this event is a t
Sanofi nears $11.6B deal for Bioverativ https://seekingalpha.com/news/3324021-sanofi-nears-11_6b-deal-bioverativ?source=feed_news_all Jan 22, 2018 - Sanofi (NYSE:SNY) is close to acquiring Bioverativ (NASDAQ:BIVV) for $105 a share, valuing the hemophilia drug maker - separated from Biogen (NASDAQ:BIIB) last year - at about $11.6B, according to mul
Novo Nordisk: Don't Spoil The Ablynx Acquisition https://seekingalpha.com/article/4138149-novo-nordisk-spoil-ablynx-acquisition?source=feed_sector_healthcare Jan 17, 2018 - Novo Nordisk has made a $3.1B bid on the Belgian biotech Ablynx.The Danish insulin giant needs acquisitions to turn to growth again.There are probably more pharma giants interested in Ablynx.Ablynx's
De-Risking Catalysts Aplenty - Cara Therapeutics https://seekingalpha.com/article/4138009-de-risking-catalysts-aplenty-cara-therapeutics?source=feed_tag_editors_picks Jan 17, 2018 - Addressing a significant concern in the medical community by providing a pain management system without addictive properties.Two upcoming catalysts are possible drivers of share price.Early data has b

Pages: 123456...59

Page 1>

Related Companies

Name Exchange Price Mkt Cap
ABT Abbott Laboratories NYSE $59.31 $103.24B
BMY Bristol-Myers Squibb Company NYSE $62.28 $101.93B
GSK GlaxoSmithKline PLC NYSE $38.2 $94.7B
LLY Eli Lilly and Company NYSE $85.49 $94.13B
AZN Astrazeneca PLC NYSE $35.44 $89.75B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for Sanofi
SNY - Google Finance https://www.google.com/finance?q=SNY Industry related info and international coverage Summary News
SNY - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=SNY Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options